LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Early Urine Collection Improves Assay for HIV-TB

By LabMedica International staff writers
Posted on 25 May 2017
Print article
Image: The Alere Determine TB LAM Ag point-of-care test screens for active TB in HIV positive patients, providing results in just minutes (Photo courtesy of Alere).
Image: The Alere Determine TB LAM Ag point-of-care test screens for active TB in HIV positive patients, providing results in just minutes (Photo courtesy of Alere).
There is an urgent need for new, accurate, and rapid non-sputum-based tuberculosis (TB) diagnostics that have high sensitivity in patients with human immunodeficiency virus (HIV/TB) co-infection with advanced immunosuppression.

Early morning urine (EMU) is accepted as a useful method for improving the concentrations of a number of antigens and analytes found in human urine. The strategy has been shown to improve the yield of urine culture for TB diagnosis.

Scientists at the University of Cape Town prospectively recruited HIV-infected adults, all over the age of 18 years, between June 2012 and February 2014 from four hospitals in South Africa. The reference standard for TB was single sputum sample positive liquid TB culture and/or Xpert MTB/RIF assay. Paired samples of EMU and random urine were collected from each patient.

The lateral flow lipoarabinomannan assay (LF-LAM) was done on random urine samples at the bedside and additionally on matched fresh bedside EMU samples the following day. All samples were tested using the Alere Determine-TB LAM Ag lateral flow assay. LF-LAM was graded using the pre-January 2014, with grade 1 and 2 manufacturer-designated cut-off-points (the latter designated grade 1 after January 2014).

There were 123 HIV-infected patients who had commenced anti-TB treatment and provided matched random and EMU samples. There were 33% (41/123) who had definite TB and 67% (82/123) had probable TB. Amongst those with definite TB LF-LAM sensitivity using the grade 2 cut-off-point, increased from 12% (5/43) to 39% (16/41) with random versus EMU, respectively. Similarly, amongst probable TB, LF-LAM sensitivity increased from 10% (8/83) to 24% (20/82). LF-LAM specificity was not determined.

The authors concluded that the study highlights the diagnostic implications of the timing of sample collection with EMU testing significantly improving LF-LAM sensitivity in hospitalized TB/HIV co-infected patients. Factors known to affect LAM concentration, such as CD4 cell count, age and culture/Xpert MTB/RIF status were not associated with an increased LF-LAM grade. The data presented have implications for clinical practice. The study was published on May 12, 2017, in the journal BMC Infectious Diseases.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.